X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gamma-Aminobutyric Acid,Alprazolam
Therapeutic Area: Endocrinology Product Name: Remygen
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
The Swedish Medical Products Agency has approved an amendment to ReGenerate-1 to investigate Remygen®'s preventive effects on hypoglycaemia (severely reduced blood sugar level) in individuals with long-term type 1 diabetes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): rhGAD65
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Details:
The patents protect the administration method of Diamyd® that is now being evaluated in the Phase IIb trial DIAGNODE-2, which previously showed positive results in the Phase I/II trial DIAGNODE-1.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
